Can the GH100 ACT be used to monitor heparin in Lupus anticoagulant?
Research type
Research Study
Full title
Evaluation of the Werfen GEM Hemochron 100 activated clotting time (ACT) point of care device in the therapeutic monitoring of unfractionated heparin in patients with Lupus anticoagulant whilst undergoing cardiopulmonary bypass.
IRAS ID
360382
Contact name
Claire L Rowlandson
Contact email
Sponsor organisation
Blackpool Teaching Hospitals Nhs Foundation Trust
Duration of Study in the UK
2 years, 9 months, 30 days
Research summary
Lupus anticoagulant is a type of molecule (antibody) in the circulation that may cause interference in some laboratory tests used to monitor blood clotting (how the body stops bleeding). This means tests that would be normal in someone without Lupus anticoagulant may appear abnormal in someone with Lupus anticoagulant. Therefore, these tests become unreliable.
The aim of this research is to evaluate the effect the Lupus anticoagulant has on these tests, to provide a better way of monitoring a blood thinner (heparin) used in open heart surgery, in patients with a Lupus anticoagulant.
Current standard care is to monitor the heparin in these patients using a test carried out in a laboratory in another area of the hospital. This research is to evaluate a test (the GEM Hemochron 100 ACT) that can be used within the operating theatre, removing the need to transport the blood samples to the laboratory, meaning results are available more quickly.REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
25/EE/0185
Date of REC Opinion
21 Aug 2025
REC opinion
Favourable Opinion